文献速递呼吸危重症与机械通气

术后早期经鼻高流量氧疗的系统评价与荟萃分析

High-Flow Nasal Cannula in the Immediate Postoperative Period: A Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2020-06-29

该系统评价纳入11项随机对照试验共2201例术后患者,比较经鼻高流量氧疗(HFNC)与常规氧疗(COT)或NIV的效果。与COT相比,HFNC降低再插管率(RR 0.32)和呼吸支持升级(RR 0.54),此效应可能由肥胖和/或高危患者驱动;与NIV相比,再插管率、呼吸治疗失败及ICU住院时间无差异。

要点

  • 心胸外科术后预防性HFNC可降低再插管率与呼吸支持升级风险。
  • 获益可能集中于肥胖和/或高危患者,亚组差异P=.06。
  • HFNC与NIV在再插管、呼吸治疗失败及ICU住院时间上无差异。

核心结论

  • 中等确定性证据表明,心胸外科术后预防性使用HFNC较COT可减少再插管和呼吸支持升级,效应可能由高危和/或肥胖患者驱动。
  • 支持在高危和/或肥胖的心胸外科术后患者中预防性使用HFNC。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase、Web of Science数据库。
  • 采用修订版Cochrane RoB 2工具评估偏倚风险,采用GRADE框架评价结局确定性。

主要发现

  • 与COT相比,HFNC降低再插管率(RR 0.32;95% CI 0.12-0.88;ARR 2.9%;中等确定性)。
  • 与COT相比,HFNC减少呼吸支持升级(RR 0.54;95% CI 0.31-0.94;ARR 5.8%;极低确定性)。
  • 事后亚组分析提示效应由肥胖和/或高危患者驱动(亚组差异P=.06)。
  • HFNC与COT在其他既定结局上无差异。
  • HFNC与NIV在再插管率、呼吸治疗失败或ICU住院时间上无差异。

关键数值与推荐

  • 再插管率:RR 0.32(95% CI 0.12-0.88),ARR 2.9%,中等确定性。
  • 呼吸支持升级:RR 0.54(95% CI 0.31-0.94),ARR 5.8%,极低确定性。
  • 亚组差异P=.06,提示肥胖和/或高危患者获益更明显。

临床怎么用

  • 对心胸外科术后高危和/或肥胖患者可考虑预防性使用HFNC以降低再插管风险。
  • HFNC与NIV的选择在再插管、呼吸治疗失败及ICU住院时间方面未见差异。
  • 需结合患者风险分层与肥胖状态个体化决策。

局限性

  • 仅1项RCT比较HFNC与NIV,相关结论证据有限。
  • 呼吸支持升级结局确定性为极低。
  • 亚组分析为事后分析,效应驱动因素需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have demonstrated that high-flow nasal cannula (HFNC) prevents intubation in acute hypoxic respiratory failure when compared with conventional oxygen therapy (COT). However, the data examining routine HFNC use in the immediate postoperative period are less clear. RESEARCH QUESTION: Is routine HFNC use superior to COT or noninvasive ventilation (NIV) use in preventing intubation in patients postoperatively? STUDY DESIGN AND METHODS: We comprehensively searched databases (PubMed, Embase, Web of Science) to identify randomized controlled trials (RCTs) that compared the effect of HFNC use with that of COT or NIV in the immediate postoperative period on reintubation, escalation of respiratory support, hospital mortality, ICU and hospital length of stay (LOS), postoperative hypoxemia, and treatment complications. We assessed individual study risk of bias (RoB) by using the revised Cochrane RoB 2 tool and rated certainty in outcomes by using the Grading of Recommendations Assessment, Development and Evaluation framework. RESULTS: We included 11 RCTs enrolling 2,201 patients. Ten compared HFNC with COT and one with NIV. Compared with COT use, HFNC use in the postoperative period was associated with a lower reintubation rate (relative risk [RR], 0.32; 95% CI, 0.12-0.88; absolute risk reduction [ARR], 2.9%; moderate certainty) and decreased escalation of respiratory support (RR, 0.54; 95% CI, 0.31-0.94; ARR, 5.8%; very low certainty). Post hoc subgroup analysis suggested that this effect was driven by patients who were obese and/or at high risk (subgroup differences, P = .06). We did not find differences in any of the other stated outcomes between HFNC and COT. HFNC was also no different from NIV in reintubation rate, respiratory therapy failure, or ICU LOS. INTERPRETATION: With evidence of moderate certainty, prophylactic HFNC reduces reintubation and escalation of respiratory support compared with COT in the immediate postoperative period after cardiothoracic surgery. This effect is likely driven by patients who are at high risk and/or obese. These findings support postoperative prophylactic HFNC use in the patients who are at high risk and/or obese undergoing cardiothoracic surgery.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Chaudhuri D, Granton D, Wang DX, et al. High-Flow Nasal Cannula in the Immediate Postoperative Period: A Systematic Review and Meta-analysis. Chest. 2020. PMID: 32615190. doi:10.1016/j.chest.2020.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。